An investigational targeted radiotherapy added to standard of care improved survival in men with previously treated mCRPC.
The frequency of targetable alterations was roughly 22% in patients of African ancestry and those of European ancestry.
TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT.
Results of a multicenter study reveal differences in genetic testing in patients with prostate cancer who meet NCCN guidelines compared with those who do not.
How the decline in health care visits will affect prostate cancer outcomes still needs to be determined.
Study findings suggest that men with end-stage kidney disease and localized or regional prostate cancer do not need to wait additional time for a kidney transplant because of the cancer.
Most men with metastatic castration-sensitive prostate cancer (mCSPC) in 2018 did not receive advanced therapies in addition to androgen deprivation therapy (ADT) as first-line treatment for their disease as recommended by clinical practice guidelines, according to real-world data presented at the American Society of Clinical Oncology 2021 virtual annual meeting. This lack of therapeutic intensification…
No change in receipt of definitive care reported for minorities in expansion states versus nonexpansion states
Tracer is injected into the bloodstream and lights up metastatic prostate cancer cells during PET scan
Screening intensity was predictive of disease stage and mortality risk.